ClinicalTrials.gg
CompletedNCT03434418Updated Oct 17, 2023Results posted

A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations

A Phase 2 interventional study of osimertinib in Non Small Cell Lung Cancer, sponsored by Duke University. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-17.

Sponsored by Duke University · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung — 20 open to participants now, 43 under way, 8 of them phase 3. osimertinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
80th of 90
17 · median 51
Started
2018
with 12 others
Phase 2
46 of 90
12 open now
Registered
34th of 90
by date

Among the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, this one is the 80th largest by enrollment, is one of 13 that started in 2018, is one of 46 in phase 2, and was the 34th registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

20 of the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung are open now, in 7 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About osimertinib

osimertinib: first FDA approval 2015 (TAGRISSO), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a research study to find out if a drug called, osimertinib, is safe and effective in treating advanced Non-Small Cell Lung Cancer (NSCLC) by targeting the treatment of epidermal growth factor receptor (EGFR) mutation exon 18 G719X, exon 20 S7681, or exon 21 L861Q. Patients on the study will not have had previous tyrosine kinase inhibitor (TKI) treatment.

Read the detailed description

This is a research study to find out if a drug called, osimertinib, is safe and effective in treating advanced Non-Small Cell Lung Cancer (NSCLC) by targeting the treatment of epidermal growth factor receptor (EGFR) mutation exon 18 G719X, exon 20 S7681, or exon 21 L861Q. Patients on the study will not have had previous tyrosine kinase inhibitor (TKI) treatment.

Patients who have one of the following EGRF mutations: exon 18 G719X, exon 20 S7681, or exon 21 L861Q) may be eligible to participate in this study. If enrolled into the study, the study team will give the patient a supply of the study drug, osimbertinib (80 mg) to take at home. The patient will be asked to take the study drug by mouth on days 1-28 of each study cycle. As part of this study, the patient will have blood samples other tests, exams and procedures done for study purposes and their standard of care. Patient participation in the study will last for up to 2 years after completion of the last dose of the study drug or until your condition worsens or intolerable adverse events as deemed by the study doctor.

There are possible patient risks to this study that include but are not limited to diarrhea, changes to the lining of the mouth (e.g. ulcers), rash, dry skin, itching, and nail infections.

03

Conditions studied

  • Non Small Cell Lung Cancer

Keywords

  • EGFR Mutation
  • osimertinib
  • exon 18 G719X
  • exon 20 S7681
  • exon 21 L861Q
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • EGFR mutations as performed on a CLIA certified laboratory demonstrating EGFR exon 18 G719X, exon 20 S768I, or exon 21 L861Q. Patients with compound (also referred to as multiple mutations) will be eligible provided the NSCLC demonstrates one of these mutations).
  • Histological or cytological confirmation diagnosis of Stage 4 NSCLC.
  • by 1.1 (please refer to appendix 4)
  • The following laboratory values obtained ≤ 14 days prior to study initiation.
  • Hematology: ≥ 1, 500 / ml, count, ≥ 100,000 / ml, ≥ 9.0 g / dl
  • Hepatic: or ALT \< 2.5 times if no demonstrable liver or \<5 times ULN in the presence of liver metastases
  • Total \< 1.5 times ULN if no liver metastases or \< 3 times ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinaemia) or liver metastases
  • Renal: calculated creatinine clearance of ≥ 45 ml/min or creatinine ≤1.5 x ULN
  • Have normal on evaluation QT corrected of ≤ 450 ms in males or ≤ 470 ms in females obtained from 3 electrocardiograms (ECGs), using the screening clinic ECG machine-derived QTc value
  • Cardiac of ≥ 45%
  • (ECOG) performance status of 0 or1
  • Negative pregnancy test done ≤7 days (or per institutional policy) prior to treatment, for women of only. Female must use highly effective measures, and must have a negative pregnancy test or must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening:
  • defined as aged more than 50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments.
  • Women under 50 years old would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with LH and FSH levels in the post-menopausal range for the institution
  • Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation
  • Male subjects must be willing to use barrier contraception
  • Age ≥ 18 years
  • Provision of written prior to any study-specific procedures

Exclusion criteria

Exclusion Criteria:

  • Prior therapy with EGFR TKI therapy
  • Greater than 2 lines of prior systemic therapy for non-small cell lung cancer.
  • Any cytotoxic chemotherapy or other anticancer drugs from previous treatment regimen or clinical study within 14 days of first dose of study drug.
  • Treatment with an drug within 5 half-lives of the compound
  • Other active ≤ 2 years prior to registration. EXCEPTIONS: Non-melanotic skin cancer or carcinoma-in-situ of the cervix. NOTE: If there is a history of prior malignancy, patients must not be receiving other specific treatment (i.e. hormonal therapy) for their cancer
  • Prior radiotherapy ≤ 14 days
  • Untreated symptomatic (treated brain metastases are allowed provided > 14 days have elapsed from completion of radiotherapy and patient is neurologically stable as assessed by treating physician).
  • Malabsorption syndrome, nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of osimertinib
  • Detection of concurrent EGFR mutation with exon 20 T790M, exon 19 deletion, exon 21 L858R mutation or exon 20 insertion. Patients with compound (also referred to as multiple mutations) will be excluded if the molecular testing includes one of these mutations.
  • Active pregnancy or breast-feeding: Pregnant women are excluded from this study because the effects of osimertinib on the development of the fetus are unknown, and there is potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with osimertinib, breastfeeding should be discontinued if the mother is treated with these agents.
  • Grade ≥ 2 blurred vision, conjunctivitis, corneal ulcer, dry eye, or keratitis
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    osimertinib

    Drug: osimertinib

Interventions

  • 80 mg oral administration daily

    Also known as: Tagrisso

06

What researchers measure

Primary outcomes

  1. Objective Response Rate as Assessed by the Investigator Using Response Evaluation Criteria In Solid Tumors (RECIST 1.1)

    The number of participants who have a partial response or complete response to the study drug. Complete response (CR) = Disappearance of all target lesions and reduction in the short axis measurement of all pathologic lymph nodes to ≤10 mm; partial response (PR) = ≥30% decrease in the sum of the longest diameter of the target lesions compared with baseline.

    Time frame: Up to 4 years

Secondary outcomes

  1. Progression Free Survival (PFS) as Measured by Response Evaluation Criteria In Solid Tumors (RECIST 1.1)

    Progression will be defined as time from starting study therapy to disease progression or death (whichever occurs first).

    Time frame: Up to 4 years

  2. Number of Participants With Adverse Events (AEs) as Measured by Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03

    Adverse events (regardless of attribution) observed in all enrolled participants, except for those withdrawn prior to study treatment or fail to receive study treatment for various reasons. Counts and percentages of participants who experienced any AEs are calculated.

    Time frame: Up to 4 years

  3. Overall Survival as Noted by Follow-up Via Composite of Telephone or Medical Record Review.

    Overall survival as defined as time from starting study therapy until death from any causes.

    Time frame: Up to 4 years

07

Results

Posted Oct 17, 2023

Participant flow

Participant flow — Overall Study
MilestoneOsimertinib
Started17
Completed2
Not completed15
Withdrew: Disease progression11
Withdrew: Adverse event2
Withdrew: Physician decision1
Withdrew: Decline in performance status (ps)1

Outcome measures

PrimaryObjective Response Rate as Assessed by the Investigator Using Response Evaluation Criteria In Solid Tumors (RECIST 1.1)

The number of participants who have a partial response or complete response to the study drug. Complete response (CR) = Disappearance of all target lesions and reduction in the short axis measurement of all pathologic lymph nodes to ≤10 mm; partial response (PR) = ≥30% decrease in the sum of the longest diameter of the target lesions compared with baseline.

Time frame:
Up to 4 years
Reported as:
Count of participants · Participants
Objective Response Rate as Assessed by the Investigator Using Response Evaluation Criteria In Solid Tumors (RECIST 1.1)
ParticipantsOsimertinib
Objective Response Rate as Assessed by the Investigator Using Response Evaluation Criteria In Solid Tumors (RECIST 1.1)8
SecondaryProgression Free Survival (PFS) as Measured by Response Evaluation Criteria In Solid Tumors (RECIST 1.1)

Progression will be defined as time from starting study therapy to disease progression or death (whichever occurs first).

Time frame:
Up to 4 years
Reported as:
Median · months
Progression Free Survival (PFS) as Measured by Response Evaluation Criteria In Solid Tumors (RECIST 1.1)
monthsOsimertinib
Progression Free Survival (PFS) as Measured by Response Evaluation Criteria In Solid Tumors (RECIST 1.1)10.5 (5.0 to 15.2)
SecondaryNumber of Participants With Adverse Events (AEs) as Measured by Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03

Adverse events (regardless of attribution) observed in all enrolled participants, except for those withdrawn prior to study treatment or fail to receive study treatment for various reasons. Counts and percentages of participants who experienced any AEs are calculated.

Time frame:
Up to 4 years
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) as Measured by Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03
ParticipantsOsimertinib
Diarrhea13
Fatigue9
Anorexia7
Weight loss7
Dyspnea6
Vomiting5
Abdominal pain5
Cough4
Acneiform rash4
Maculopapular Rash4
Respiratory failure1
Thromboembolic event1
SecondaryOverall Survival as Noted by Follow-up Via Composite of Telephone or Medical Record Review.

Overall survival as defined as time from starting study therapy until death from any causes.

Time frame:
Up to 4 years
Reported as:
Median · months
Overall Survival as Noted by Follow-up Via Composite of Telephone or Medical Record Review.
monthsOsimertinib
Overall Survival as Noted by Follow-up Via Composite of Telephone or Medical Record Review.13.8 (9.3 to 29.2)

Adverse events

Collected over Up to 4 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Osimertinib12/17 (70.6%)2/17 (11.8%)17/17 (100%)
Most frequent serious events
Most frequent serious events
EventOsimertinib
Respiratory failureRespiratory, thoracic and mediastinal disorders1/17
Thromboembolic eventRespiratory, thoracic and mediastinal disorders1/17
Most frequent other events
Most frequent other events
EventOsimertinib
DiarrheaGastrointestinal disorders13/17
FatigueGeneral disorders9/17
AnorexiaMetabolism and nutrition disorders7/17
Weight lossMetabolism and nutrition disorders7/17
DyspneaRespiratory, thoracic and mediastinal disorders6/17
VomitingGastrointestinal disorders5/17
Abdominal painGeneral disorders5/17
CoughRespiratory, thoracic and mediastinal disorders4/17
Acneiform rashSkin and subcutaneous tissue disorders4/17
Maculopapular rashSkin and subcutaneous tissue disorders4/17

Baseline characteristics

Age, Continuous
Age, Continuous(years)Osimertinib
Median70 (62 to 76)
Sex: Female, Male
Sex: Female, Male(Participants)Osimertinib
Female11
Male6
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Osimertinib
Hispanic or Latino0
Not Hispanic or Latino17
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Osimertinib
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American3
White12
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Osimertinib
United States17
ECOG performance status
ECOG performance status(Participants)Osimertinib
ECOG = 07
ECOG = 110
EGFR mutation subtype
EGFR mutation subtype(Participants)Osimertinib
G719X7
L861Q6
G719X/L718X1
G719X/S768I1
L861Q/S768I1
G719X/V689L1
Location of metastases
Location of metastases(Participants)Osimertinib
Bone8
Brain5
Liver5
Lung4
Lymph node8
Pleura5
08

Study locations

3 sites
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • The Ohio State University Medical Center
    Columbus, Ohio 43202, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15232, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Oct 2022, 51 months.

Results were first posted in Oct 2023, 1 year after primary completion.

Of 729 non-industry phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's 51 months is close to that.

Counting every sponsor, half of 1,046 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2018
First posted
Feb 15, 2018
StartActual
Jun 30, 2018
Primary completionActual
Oct 12, 2022
CompletionActual
Oct 12, 2022
Results first posted
Oct 17, 2023
Last update
Oct 17, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03434418
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Feb 15, 2018
Start date
Jun 30, 2018
Primary completion
Oct 12, 2022
Completion
Oct 12, 2022
Results posted
Oct 17, 2023
Last update
Oct 17, 2023

Study contacts

Thomas Stinchcombe, MD
principal investigator · Duke University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Osimertinib

Start the discussion